Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008838 | 0.92 | HTR2A (0.56) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6008823 | 0.85 | UTS2R (0.61) | HTR2AKCNH2CCR5 | |
| SCHEMBL5790046 | 0.81 | CARM1 (0.58) | HTR2ACCR5KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6007208 | 0.81 | HTR2A (0.52) | HTR2AKCNH2CCR3CCR5KDM4E | |
| SCHEMBL5758023 | 0.79 | HTR2A (0.61) | HTR2AKCNH2CCR3CCR5KDM4E | |
| SCHEMBL5760413 | 0.79 | HTR2A (0.58) | HTR2ACCR5KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6007244 | 0.79 | SLC6A2 (0.56) | CCR3 | |
| Hydrochloric Acid SCHEMBL6008822 | 0.78 | HTR2A (0.60) | HTR2AKCNH2CCR3CCR5KDM4E | |
| SCHEMBL11758953 | 0.78 | KCNH2 (0.66) | HTR2AKCNH2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL27298639 | 0.75 | HTR2A (0.56) | HTR2AKCNH2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | claimed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | claimed |
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | HTR2A 58/4885KCNH2 1161/4885CCR3 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.